<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680145</url>
  </required_header>
  <id_info>
    <org_study_id>15-006186</org_study_id>
    <nct_id>NCT02680145</nct_id>
  </id_info>
  <brief_title>Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use</brief_title>
  <official_title>Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective trial of pessary use prior to reconstructive pelvic&#xD;
      floor surgery for pelvic organ prolapse. The goal of the study is to evaluate the change in&#xD;
      pelvic floor symptoms with pessary use and subsequent reconstructive surgery. Additionally,&#xD;
      we will assess the impact that preoperative pessary use has on patient self-reported&#xD;
      preparedness for surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is anticipated that this trial will define the clinical utility of routine preoperative&#xD;
      pessary placement, and by shaping patient expectations and increasing preparedness for&#xD;
      surgery, we anticipate improving satisfaction and quality of life.&#xD;
&#xD;
      At the initial office visit baseline symptoms are evaluation with validated questionnaire.&#xD;
&#xD;
      The patients' will undergo pessary fitting at least 7 days (but no more than 28 days) prior&#xD;
      to scheduled surgical prolapse repair.&#xD;
&#xD;
      Symptomatic change from baseline will be assessed with validated questionnaire&#xD;
      preoperatively.&#xD;
&#xD;
      The pessary will be removed at the time of surgery, and the patient will undergo surgical&#xD;
      correction of their pelvic organ prolapse (including all restorative surgical procedures,&#xD;
      abdominal and transvaginal). A concomitant anti-incontinence procedure will be performed at&#xD;
      the discretion of the treating physician in consultation with the patient.&#xD;
&#xD;
      The patients' symptomatic outcome from surgery will then be reassessed by validated&#xD;
      questionnaire at 6 weeks and 3 months postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Score</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>Number of participants considered treatment success assessed using the 7-point Likert scale of the Patient Global Impression of Improvement (PGI-I) of 1= very much better and 7=very much worse. Patient's will be considered treatment success if they answer &quot;much better&quot; or &quot;very much better&quot; on the PGI-I scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prolapse Symptom Severity</measure>
    <time_frame>Baseline, 3 month post surgery</time_frame>
    <description>Mean value of score on self-reported Pelvic Organ Prolapse Distress Inentory-6 (POPDI-6) questionnaire. Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bother of Bladder/Vaginal/Bowel Symptoms</measure>
    <time_frame>Baseline, 3 month post surgery</time_frame>
    <description>Mean value of score on self-reported Floor Impact Questionnaire-7 (PFIQ-7). Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overactive Bladder Symptom Score (OABSS)</measure>
    <time_frame>Baseline, 3 month post surgery</time_frame>
    <description>Mean value of score on self-reported Overactive Bladder Symptom Score (OABSS) questionnaire. Minimum scale score = 0; maximum scale score = 15 and a higher score indicates worse outcome.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Vaginal Vault Prolapse</condition>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Uterine Prolapse</condition>
  <condition>Pelvic Floor Prolapse</condition>
  <arm_group>
    <arm_group_label>Preoperative Pessary Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Preoperative Pessary Use</intervention_name>
    <description>Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
    <arm_group_label>Preoperative Pessary Use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 18 years of age&#xD;
&#xD;
          -  With symptomatic pelvic organ prolapse&#xD;
&#xD;
          -  Electing for surgical repair of pelvic organ prolapse (transvaginal or transabdominal)&#xD;
             at least 7 days after office consultation&#xD;
&#xD;
          -  Understand and have signed written informed consent for preoperative pessary&#xD;
             placement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous use of a pessary for pelvic organ prolapse&#xD;
&#xD;
          -  Patients undergoing obliterative prolapse surgery (i.e. Colpocleisis),&#xD;
&#xD;
          -  Are scheduled for surgery for pelvic organ prolapse less than 7 days after office&#xD;
             consultation or greater than 4 weeks after office consultation&#xD;
&#xD;
          -  Have an isolated rectocele&#xD;
&#xD;
          -  Have allergies to both latex and silicone&#xD;
&#xD;
          -  Have an active pelvic infection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Occhino, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Linder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John A. Occhino</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics-Gynecology</investigator_title>
  </responsible_party>
  <keyword>Pessary</keyword>
  <keyword>Prolapse</keyword>
  <keyword>Cystocele</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02680145/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Preoperative Pessary Use</title>
          <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preoperative Pessary Use</title>
          <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Score</title>
        <description>Number of participants considered treatment success assessed using the 7-point Likert scale of the Patient Global Impression of Improvement (PGI-I) of 1= very much better and 7=very much worse. Patient's will be considered treatment success if they answer &quot;much better&quot; or &quot;very much better&quot; on the PGI-I scale.</description>
        <time_frame>3 months postoperatively</time_frame>
        <population>40 participants completed the PGI-I form 3 months after surgery for data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Pessary Use</title>
            <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Score</title>
          <description>Number of participants considered treatment success assessed using the 7-point Likert scale of the Patient Global Impression of Improvement (PGI-I) of 1= very much better and 7=very much worse. Patient's will be considered treatment success if they answer &quot;much better&quot; or &quot;very much better&quot; on the PGI-I scale.</description>
          <population>40 participants completed the PGI-I form 3 months after surgery for data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prolapse Symptom Severity</title>
        <description>Mean value of score on self-reported Pelvic Organ Prolapse Distress Inentory-6 (POPDI-6) questionnaire. Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.</description>
        <time_frame>Baseline, 3 month post surgery</time_frame>
        <population>Data was available for analysis on 36 participants which completed questionnaire at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Pessary Use</title>
            <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Prolapse Symptom Severity</title>
          <description>Mean value of score on self-reported Pelvic Organ Prolapse Distress Inentory-6 (POPDI-6) questionnaire. Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.</description>
          <population>Data was available for analysis on 36 participants which completed questionnaire at both time points.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline score vs Follow-up score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bother of Bladder/Vaginal/Bowel Symptoms</title>
        <description>Mean value of score on self-reported Floor Impact Questionnaire-7 (PFIQ-7). Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.</description>
        <time_frame>Baseline, 3 month post surgery</time_frame>
        <population>Data was available for analysis on 40 participants which completed questionnaire at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Pessary Use</title>
            <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Bother of Bladder/Vaginal/Bowel Symptoms</title>
          <description>Mean value of score on self-reported Floor Impact Questionnaire-7 (PFIQ-7). Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.</description>
          <population>Data was available for analysis on 40 participants which completed questionnaire at both time points.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline score vs Follow-up score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overactive Bladder Symptom Score (OABSS)</title>
        <description>Mean value of score on self-reported Overactive Bladder Symptom Score (OABSS) questionnaire. Minimum scale score = 0; maximum scale score = 15 and a higher score indicates worse outcome.</description>
        <time_frame>Baseline, 3 month post surgery</time_frame>
        <population>Data was available for analysis on 32 participants which completed questionnaire at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Pessary Use</title>
            <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Symptom Score (OABSS)</title>
          <description>Mean value of score on self-reported Overactive Bladder Symptom Score (OABSS) questionnaire. Minimum scale score = 0; maximum scale score = 15 and a higher score indicates worse outcome.</description>
          <population>Data was available for analysis on 32 participants which completed questionnaire at both time points.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline score vs Follow-up score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for each subject through study participation, duration of approximately 3 months after pelvic surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Preoperative Pessary Use</title>
          <description>All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse&#xD;
Preoperative Pessary Use: Pessary use for 1-4 weeks prior to surgical prolapse repair</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Exacerbated chronic constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction on abdomen at surgical site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia post operative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia post operative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pelvic floor myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Incidental cystotomy repair (1 cm)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dryness with itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vaginal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vaginal Bleeding Post operative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Ureteral vaginal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John A. Occhino</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>(507) 538-5883</phone>
      <email>Occhino.John@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

